Nanobiotix (LSE:0QAV) - Stock Price, News & Analysis

0QAV Stock Overview

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs.

About the company

0QAV fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Revenue is forecast to grow 24.47% per year

Analysts in good agreement that stock price will rise by 96.5%

Risk Analysis

Negative shareholders equity

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Nanobiotix S.A. Competitors

Oxford Biomedica

LSE:OXB

UK£215.0m

Bioventix

AIM:BVXP

UK£233.6m

Avacta Group

AIM:AVCT

UK£158.1m

NIOX Group

AIM:NIOX

UK£283.2m

Price History & Performance

Summary of all time highs, changes and price drops for Nanobiotix
Historical stock prices
Current Share Price	€5.60
52 Week High	€10.38
52 Week Low	€1.62
Beta	1.25
1 Month Change	-2.35%
3 Month Change	-21.24%
1 Year Change	133.82%
3 Year Change	-58.40%
5 Year Change	-51.39%
Change since IPO	-79.26%

Recent updates

Shareholder Returns

	0QAV	GB Biotechs	GB Market
7D	5.2%	-1.9%	-0.9%
1Y	133.8%	-30.5%	-1.8%

Return vs Industry: 0QAV exceeded the UK Biotechs industry which returned -30.5% over the past year.

Return vs Market: 0QAV exceeded the UK Market which returned -1.8% over the past year.

Price Volatility

Is 0QAV's price volatile compared to industry and market?
0QAV volatility
0QAV Average Weekly Movement	4.7%
Biotechs Industry Average Movement	7.4%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0QAV's share price has been volatile over the past 3 months.

Volatility Over Time: 0QAV's weekly volatility has decreased from 25% to 5% over the past year.

About the Company

Founded	Employees	CEO	Website
2003	101	Laurent Levy	www.nanobiotix.com

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.

Nanobiotix S.A. Fundamentals Summary

How do Nanobiotix's earnings and revenue compare to its market cap?
0QAV fundamental statistics
Market cap	€270.89m
Earnings (TTM)	-€58.78m
Revenue (TTM)	€6.74m

40.2x

P/S Ratio

-4.6x

P/E Ratio

Is 0QAV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QAV income statement (TTM)
Revenue	€6.74m
Cost of Revenue	€0
Gross Profit	€6.74m
Other Expenses	€65.52m
Earnings	-€58.78m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Apr 24, 2024

Earnings per share (EPS)	-1.25
Gross Margin	100.00%
Net Profit Margin	-872.15%
Debt/Equity Ratio	-90.6%

How did 0QAV perform over the long term?

See historical performance and comparison

0QAV Stock Overview

Rewards

Risk Analysis

Nanobiotix S.A. Competitors

LSE:OXB

UK£215.0m

AIM:BVXP

UK£233.6m

AIM:AVCT

UK£158.1m

AIM:NIOX

UK£283.2m

Price History & Performance

Recent News & Updates

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Recent updates

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

New minor risk - Financial position

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

New minor risk - Financial position

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

New minor risk - Shareholder dilution

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

No longer forecast to breakeven

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

Forecast to breakeven in 2024

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Forecast to breakeven in 2024

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Full year 2021 earnings released: €1.35 loss per share (vs €1.38 loss in FY 2020)

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

First half 2021 earnings released: €0.88 loss per share (vs €0.91 loss in 1H 2020)

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

Full year 2020 earnings released: €1.38 loss per share (vs €2.35 loss in FY 2019)

Full year 2020 earnings released

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

Nanobiotix Announces First Patient Injected with NBTXR3 in Esophageal Cancer

New 90-day high: €17.00

NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

New 90-day high: €13.86

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $99 million.

Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces Positive New Pre-Clinical Data Suggesting Radioenhancer NBTXR3 Could Have A Significant Impact in Immunotherapy

Nanobiotix Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3

New 90-day low: €6.05

Nanobiotix Provides Updates on Global Clinical Development Plan for First-In-Class Radioenhancer Nbtxr3 At Astro 2020

NANOBIOTIX Announces First Patient Injected with Nbtxr3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials from U.S. FDA

New 90-day low: €6.25

First half earnings released

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of €20.13 million.

Shareholder Returns

Price Volatility